on GENOWAY (EPA:ALGEN)
Half-year review of the liquidity contract for genOway as of December 31, 2025
The biotechnology company genOway has released key figures for its liquidity contract for the second half of 2025, managed by Portzamparc - Groupe BNP Paribas. As of December 31, 2025, the liquidity account held 16,002 genOway shares and €32,256.26 in cash. Compared to the balance sheet as of June 30, 2025, the number of shares decreased from 18,270 to 16,002, while cash increased from €25,115.23 to €32,256.26.
Since the contract was established on December 31, 2018, a significant decrease in the number of shares, initially at 28,232, has been observed. During the second half of 2025, 31,316 shares were purchased for €86,569.72, while 33,584 shares were sold for €93,710.75.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENOWAY news